AVROBIO Stock Forecast, Price & News

-0.13 (-2.06 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.67 million shs
Average Volume332,494 shs
Market Capitalization$269.57 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.



Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.53 out of 5 stars

Medical Sector

91st out of 1,350 stocks

Biological Products, Except Diagnostic Industry

12th out of 193 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO
or view top-rated stocks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for AVROBIO

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) issued its earnings results on Wednesday, August, 4th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.08.
View AVROBIO's earnings history

How has AVROBIO's stock price been impacted by COVID-19 (Coronavirus)?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 65.7% and is now trading at $6.18.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AVRO?

10 brokerages have issued twelve-month price objectives for AVROBIO's shares. Their forecasts range from $10.00 to $36.00. On average, they expect AVROBIO's share price to reach $25.40 in the next year. This suggests a possible upside of 311.0% from the stock's current price.
View analysts' price targets for AVROBIO
or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Geoff MacKay, President, Chief Executive Officer & Director
  • Matt Arnold, Head-Operations
  • Erik Ostrowski, Chief Financial Officer & Treasurer
  • Christopher Mason, Chief Scientific Officer
  • Kim Raineri, Chief Manufacturing & Technology Officer

Who are some of AVROBIO's key competitors?

What other stocks do shareholders of AVROBIO own?


(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (11.21%), BlackRock Inc. (8.46%), State Street Corp (6.35%), Federated Hermes Inc. (5.56%), GMT Capital Corp (4.89%) and Vanguard Group Inc. (3.91%). Company insiders that own AVROBIO stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends for AVROBIO

Which institutional investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, UBS Asset Management Americas Inc., Emerald Advisers LLC, Vanguard Group Inc., FMR LLC, Millennium Management LLC, and DekaBank Deutsche Girozentrale.
View insider buying and selling activity for AVROBIO
or view top insider-selling stocks.

Which institutional investors are buying AVROBIO stock?

AVRO stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada, GMT Capital Corp, State Street Corp, Federated Hermes Inc., Citigroup Inc., Point72 Asset Management L.P., Goldman Sachs Group Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for AVROBIO
or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $6.18.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $269.57 million. The company earns $-119,710,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 121 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is

Where are AVROBIO's headquarters?

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 914-8420 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.